{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:11:38Z","timestamp":1761894698858,"version":"3.33.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1136\/ard.2008.089979","type":"journal-article","created":{"date-parts":[[2008,3,29]],"date-time":"2008-03-29T11:11:11Z","timestamp":1206789071000},"page":"531-535","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":113,"title":["Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis"],"prefix":"10.1016","volume":"68","author":[{"given":"M K","family":"de Vries","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I E","family":"van der Horst-Bruinsma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M T","family":"Nurmohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L A","family":"Aarden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S O","family":"Stapel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M J L","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J C","family":"van Denderen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B A C","family":"Dijkmans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G J","family":"Wolbink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2008.089979_bib1","first-page":"S67","article-title":"Treatment of ankylosing spondylitis with disease modifying antirheumatic drugs.","volume":"20","author":"van der Horst-Bruinsma","year":"2002","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.2008.089979_bib2","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.089979_bib3","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1136\/ard.2004.020875","article-title":"Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.","volume":"63","author":"Calin","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2008.089979_bib4","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.","volume":"54","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.089979_bib5","first-page":"40","article-title":"The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis.","volume":"25","author":"Dore","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.2008.089979_bib6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJM199707173370301","article-title":"Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.","volume":"337","author":"Moreland","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2008.089979_bib7","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1136\/ard.2006.065615","article-title":"Clinical response to adalimumab: The relationship with anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis.","volume":"66","author":"Bartelds","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2008.089979_bib8","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1136\/ard.2006.057745","article-title":"Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation.","volume":"66","author":"de Vries","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2008.089979_bib9","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/ard.2005.041137","article-title":"ASAS\/EULAR recommendations for the management of ankylosing spondylitis.","volume":"65","author":"Zochling","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2008.089979_bib10","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/ard.62.9.817","article-title":"International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis.","volume":"62","author":"Braun","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2008.089979_bib11","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1136\/ard.2005.040758","article-title":"First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis.","volume":"65","author":"Braun","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2008.089979_bib12","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/BF02991163","article-title":"IgG4 as a blocking antibody.","volume":"1","author":"Aalberse","year":"1983","journal-title":"Clin Rev Allergy"},{"key":"10.1136\/ard.2008.089979_bib13","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/art.21671","article-title":"Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis.","volume":"54","author":"Wolbink","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.089979_bib14","unstructured":"Enbrel Inc,. Enbrel\u00ae (etanercept) for subcutanious injection. http:\/\/www.enbrel.com\/prescribing-information.jsp (accessed 26 September 2005)."},{"key":"10.1136\/ard.2008.089979_bib15","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.089979_bib16","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1345\/aph.19126","article-title":"The pharmacokinetics of etanercept in healthy volunteers.","volume":"34","author":"Korth-Bradley","year":"2000","journal-title":"Ann Pharmacother"},{"key":"10.1136\/ard.2008.089979_bib17","doi-asserted-by":"crossref","first-page":"267","DOI":"10.5414\/CPP42267","article-title":"Population-based pharmacokinetics of the soluble TNFr etanercept: a clinical study in 43 patients with ankylosing spondylitis compared with post hoc data from patients with rheumatoid arthritis.","volume":"42","author":"Zhou","year":"2004","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1136\/ard.2008.089979_bib18","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1177\/0091270004273321","article-title":"Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein.","volume":"45","author":"Zhou","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1136\/ard.2008.089979_bib19","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/art.20019","article-title":"Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.","volume":"50","author":"Keystone","year":"2004","journal-title":"Arthritis Rheum"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724425582?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724425582?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2008.089979","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T05:16:32Z","timestamp":1737263792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724425582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["S0003496724425582"],"URL":"https:\/\/doi.org\/10.1136\/ard.2008.089979","relation":{},"ISSN":["0003-4967"],"issn-type":[{"type":"print","value":"0003-4967"}],"subject":[],"published":{"date-parts":[[2009,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2008.089979","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 2009 Published by Elsevier Inc. Publishing Group and European League Against Rheumatism. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}